Apogee Therapeutics, Inc.
APGE
Pozycja w akcjach
#2361
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Cena akcji
$135.07
Ostatnia synchronizacja: 2026-09-04
Kapitalizacja rynkowa
$8.36B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
137.21%
Kraj
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategoria
Healthcare
Wskaźnik P/B dla Apogee Therapeutics, Inc. (APGE)
Wskaźnik P/B na dzień October 2026 TTM: 8.53
Według najnowszych raportów finansowych i ceny akcji Apogee Therapeutics, Inc., obecny wskaźnik P/B (TTM) wynosi 8.53. Na koniec 2023 wynosił 3.73.
Historia wskaźnika P/B dla Apogee Therapeutics, Inc. od 2022 do 2026
Wskaźnik P/B na koniec każdego roku
| Rok | Wskaźnik P/B | Zmień |
|---|---|---|
| 2026 (TTM) | 8.53 | 144.42% |
| 2024 | 3.49 | -6.37% |
| 2023 | 3.73 | -50.80% |
| 2022 | 7.57 | 0.00% |
Wskaźnik P/B dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/B | Różnica wskaźnika P/B | Kraj |
|---|---|---|---|
| 6.251 | -26.72% |
US
|
|
| 13.2547 | 55.39% |
US
|
|
| 4.208 | -50.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -27.52% |
NL
|
